サクシネート受容体への種選択的抗体結合の構造的基礎
Matthias Haffke1,2, Dominique Fehlmann3, Gabriele Rummel4
1Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. matthias.haffke@novartis.com.
Nature
|October 25, 2019
まとめ
研究者は,サクシネート受容体SUCNR1の結晶構造を決定し,その不活性状態と抗体結合に関する洞察を明らかにした. この構造情報は,サクシネートシグナル伝達に関連した疾患の標的治療の開発に役立ちます.
科学分野:
- 生物化学
- 分子生物学
- 薬理学について
背景:
- ミトコンドリアの反応性酸素種を調節し,SUCNR1受容体 (GPR91) を通して免疫の危険信号として作用する.
- SUCNR1はサクシネート信号を高血圧,血管新生,炎症と結びつけ 潰瘍性大腸炎,肝硬化,糖尿病,関節リウマチなどの疾患に 関与している.
- この受容体は病原性において重要な治療標的となる.
研究 の 目的:
- ネズミのSUCNR1の高解像度結晶構造を明らかにする.
- 種の選択的な抗体結合に関与する主要な残留物を特定する.
- 薬の発見のために選択的抗体と結合した人間化されたラットSUCNR1の構造を決定する.
主な方法:
- ネズミのSUCNR1の高解像度結晶構造を細胞内ナノボディで決定する.
- 構造に基づく変異性および放射性結合に関する研究
- ヒト化したネズミのSUCNR1抗体複合体の構造の分子モデリングと決定.
主要な成果:
- ナノボディに結合した無活性ラットSUCNR1の結晶構造が決定された.
- 種の選択的な抗体結合を媒介する主要な残留物は特定された.
- 選択抗体 (NF- 56- EJ40) と複合したヒト化されたラットSUCNR1の高解像度構造は解消された.
結論:
- SUCNR1の非活性状態と抗体結合に関する構造的洞察は,構造に基づく薬剤発見の基盤を提供します.
- SUCNR1の構造と選択性を理解することは,そのin vitroとin vivoの機能を明らかにするために極めて重要です.
- この研究は,様々な疾患におけるSUCNR1媒介経路を標的とした新しい治療法の開発を容易にする.
関連する概念動画
Dose-Response Relationship: Selectivity and Specificity
9.4K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.4K
Drug-Receptor Interaction: Antagonist
4.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.6K
Depolarizing Blockers: Pharmocokinetics
541
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
541
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.6K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.6K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.7K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.7K
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K


